(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Essential Thrombocythemia pipeline constitutes 6+ key companies continuously working towards developing 6+ Essential ...

Over the past 35 years, interferons have been explored in various formulations for the management of Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), such as essential ...

While in nursing school, a patient recognized potential signs of a blood disorder and advocated for further testing, leading to an early diagnosis of essential thrombocythemia. Despite initial ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and efficacy of INCA033989, a novel, first in ...

LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by GlaxoSmithKline for OJJAARA™ (momelotinib). OJJAARA is a ...

Patients with essential thrombocythemia faced an average delay of 26.5 months between their first high platelet count and diagnosis. Patients experienced a significant delay in receiving an essential ...

Hemorrhagic events post-diagnosis in patients with ET significantly increase mortality risk, more than thrombosis or disease progression. Intracranial hemorrhage is the most lethal bleeding ...

Swedish Orphan Biovitrum Ab (($GB:0MTD)) announced an update on their ongoing clinical study. Swedish Orphan Biovitrum is conducting a Phase 3 ...